Biotricity wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure

Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD’).

The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification schemes do not consider stages of CKD. Additionally, the detection of stroke-risk variations due to dialysis requires real-time risk monitoring, which is unavailable to date.

Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are pleased to be working on this critically important project with the NIH, further validating our current artificial intelligence technology and entering into a new disease profile for us in CKD. The real-time monitoring of stroke risk in CKD patients, and in particular for those undergoing dialysis, is likely to influence adopted therapeutic strategies and promote a more personalized therapeutic approach. Better care and prevention through monitoring of these high-risk patients is expected to reduce mortality rates and the high per-capita cost of treatment, which is currently five-times higher than the average healthcare spend. The completion of this feasibility study will pave the road for further development and optimization of the AI-based algorithm for stroke prediction in CKD patients. This will widen the application to a larger patient demographic, thereby validating the predictive algorithm for the potential benefit of patients with other chronic diseases.”

Biotricity is developing Bioflux-AI, an innovative system for real-time monitoring and prediction of stroke episodes in CKD patients. Bioflux-AI combines an FDA-approved, high-precision, small mobile cardiac telemetry (MCT) device with AI-driven algorithms specifically trained for the prediction of stroke in stage 4 and stage 5 CKD patients. Biotricity has previously generated and validated algorithms for the automated detection of ECG abnormalities, including Atrial Fibrillation (AF).

Given the strong association of AF with increased risk of blood clot formation and hence, ischemic stroke in CKD patients, Biotricity proposes to combine the detection of this arrhythmia with other stroke risk factors of CKD patients (age, weight, height, BMI, CKD status, diabetes, heart disease) and ECG parameters to predict stroke risk in real-time.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.